Design [acty]    
Rationale [idcn]    
Trial [resa]    
Test [lbpr]    
Efficacy [qlco]    
Purified [ftcn]    
Long [qlco]    
Chain [mnob]    
treatment [ftcn]    
Non-alcoholic Fatty Liver Disease [dsyn]    
Background [cnce]    
Non-alcoholic Fatty Liver Disease [dsyn]    
Represent [acty]    
Ranges [qnco]    
Liver [bpoc]    
condition [dsyn]    
Simple [qlco]    
Fatty Liver [dsyn]    
progress [ftcn]    
End Stage Liver Disease [dsyn]    
Transplant [topp]    
Non-alcoholic Fatty Liver Disease [dsyn]    
Common [qnco]    
Population [qnco]    
Certain [qlco]    
Sub- [spco]    
Group [idcn]    
g% [qnco]    
Diabetes Type 2 [dsyn]    
patient [podg]    
Affect [ftcn]    
Non-alcoholic Fatty Liver Disease [dsyn]    
Not [ftcn]    
Only [qnco]    
cause [ftcn]    
End Stage Liver Disease [dsyn]    
Hepatocellular carcinoma [neop]    
Independence [idcn]    
Risk factor [qnco]    
Diabetes Type 2 [dsyn]    
Cardiovascular disease [dsyn]    
effectiveness treatment [qlco]    
Non-alcoholic Fatty Liver Disease [dsyn]    
Needed [qlco]    
Object [inpr]    
studies [mnob]    
Test [ftcn]    
Hypothesis [idcn]    
treatment [ftcn]    
High dose [qnco]    
Purified [ftcn]    
Effect [qlco]    
Liver [bpoc]    
Percentage [qnco]    
/B [qnco]    
Two [qnco]    
Histologic [ftcn]    
derivation [qlco]    
Biomarker [clna]    
Score [qnco]    
Fibrosis, Liver [dsyn]    
Design [acty]    
DOUBLE BLIND [resa]    
placebo-controlled [resa]    
Trial [resa]    
Participant [popg]    
Non-alcoholic Fatty Liver Disease [dsyn]    
month [tmco]    
treatment [ftcn]    
g/day [qnco]    
Purified [ftcn]    
g/day [qnco]    
placebo [topp]    
Erythrocyte [cell]    
Percentage [qnco]    
Proxy [grup]    
Hepatic [blor]    
Gas Chromatography [lbpr]    
Liver [bpoc]    
Percentage [qnco]    
Measurable [qlco]    
Three [qnco]    
Discrete [qlco]    
Hepatic zone [blor]    
Magnetic Resonance Spectroscopy [diap]    
Measurable [qlco]    
Body Fat Distribution [fndg]    
Physical activity [dora]    
Ranges [qnco]    
Risk factor [qnco]    
Method [inpr]    
Recruitment [acty]    
Start [qlco]    
End [qlco]    
Identifiable [qlco]    
Potential [qlco]    
Participant [popg]    
Participant [popg]    
Meet [idcn]    
Inclusion Criteria [qlco]    
studies [mnob]    
Approval [qlco]    
Local [spco]    
Ethics Committee [prog]    
[c] [qnco]    
Rights [qlco]    
Reservation [acty]    
